Original document(7 pages)  中文版
    The present invention belongs to the field of molecular immunology and relates to a kind of contraception vaccine cross-linked with molecular adjuvant. Three copy C3d and hCG beta serving as molecular adjuvant are constituted via gene cloning into eukaryote expressing plasmid pCMV4, and the fusion plasmid is used as DNA contraception vaccine to immunize human body or animal to produce generation-resisting effect. By means of expressing corresponding product via gene engineering to form protein contraception vaccine and immunizing human body or animal, the same generation-resisting effect may be produced.
Application Number
申请号
03108565 Application Date
申请日
2003.03.28
Title 名称 Contraception vaccine cross-linked with molecular adjuvant
Publication Number
公开号
1440811 Publication Date
公开日
2003.09.10
Approval Pub. Date Granted Pub. Date
International Classification 分类号 A61K39/39,A61P15/18
Applicant(s) Name
申请人
Gynaecology and Obstetrics Hospital attached to Fudan Univ.
Address 地址 200011
Inventor(s) Name 发明人
Attorney & Agent 代理人 bao zhaoyi
More information 更  多  信  息


 Related patents information
Process for preparing human chorionic gonadotropin beta subunit
Application of cyclosporin A in preparing anti-abortion medicine
A fusion protein contraception vaccine with molecular adjuvant and its preparation
Google
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.